J&J’s Bedaquiline: 10 Days Early For GAIN Incentive
This article was originally published in RPM Report
Executive Summary
Janssen Pharmaceuticals’ MDR-TB compound bedaquiline has the right indication to get an extra five years of exclusivity through the Generating Antibiotic Incentives Now Act – but the NDA was submitted too early to qualify.
You may also be interested in...
TB Drug Headed Toward Accelerated Approval: Another Wrinkle for Priority Review Vouchers
A positive advisory committee for Janssen’s bedaquiline means the second priority review voucher is probably on its way. And it would be the first for an accelerated approval.
FDA Cuts Priority Review Voucher Fee By 32%; J&J In Line For Next Voucher?
By taking into account the incremental costs of priority review and eliminating the IND aspect of the calculation, the agency reduces the fee to redeem a tropical disease priority review voucher to $3.6 million in fiscal year 2013. That may benefit J&J, assuming a pending tuberculosis agent is approved by FDA.
TB Drug Development: An Attractive Public Health Project for FDA
FDA is joining in the push for new tuberculosis treatments, with Commissioner Hamburg lending support for a renewed development effort. The challenge is to translate podium appearances into changes that will make for a more attractive development pathway. The primary goal is to find a way to study multi-drug regimens, including regimens with more than one investigational compound. FDA is engaging on that thorny regulatory issue.